Edgewise Therapeutics Q3 EPS $(0.41) Misses $(0.40) Estimate
Portfolio Pulse from Benzinga Newsdesk
Edgewise Therapeutics reported Q3 losses of $(0.41) per share, missing the analyst consensus estimate of $(0.40) by 2.5 percent. This represents a 20.59 percent increase in losses compared to the same period last year.
November 09, 2023 | 1:26 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Edgewise Therapeutics' Q3 earnings per share missed estimates, with losses increasing by 20.59% compared to the same period last year.
Edgewise Therapeutics reported a larger than expected loss for Q3, which is likely to negatively impact investor sentiment and potentially lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100